NextBio Announces Translational Medicine Partnership with Sanofi
News May 02, 2013
NextBio has announced a multi-year collaboration with Sanofi aimed at using NextBio Clinical to incorporate patient omics and clinical data into Sanofi's drug research and development, as part of Sanofi's Translational Medicine for Patients (TM4P) program.
NextBio will provide Sanofi with the NextBio Clinical platform for aggregation, standardization and analysis of patient clinical data, next generation sequencing (NGS) and other molecular data across public data sources, Sanofi clinical trials and Sanofi hospital partners.
NextBio's unique data integration platform, user interface and real-time Big Data analytics will allow Sanofi biologists and clinicians to tap into a vast, growing collection of patient data as it becomes available, as a key enabling technology for translational and clinical research.
"Sanofi has long used NextBio as an important component of the company's preclinical research programs," said Saeid Akhtari, President and Chief Executive Officer of NextBio.
Akhtari continued, "The new translational medicine partnership with NextBio, with its Big Data Genomics capabilities, will enable Sanofi to implement patient-centered approaches across all stages of translational and clinical research in several major therapeutic areas, including oncology and diabetes."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.